During the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scientists from Plexium Inc. presented the identification of a new class of potent, selective, cereblon (CRBN)-based molecular glue degraders of CDK2 using its proprietary monovalent degrader platform.
At the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers from Aurigene Oncology Ltd. presented the discovery and clinical characterization of novel macrocyclic KIF18A inhibitors.
Researchers from the US National Institutes of Health (NIH) and Marengo Therapeutics Inc. previously developed a first-in-class, bifunctional therapeutic molecule (STAR-0602) that selectively activates V β6 and V β10 T-cell receptor-expressing T cells and boosts antitumor responses in human ex vivo tumor models.
Hutchmed (China) Ltd. has developed HMPL-A251, a novel HER2 antibody-drug conjugate (ADC) designed to deliver a potent PI3K/PIKK inhibitor directly to tumor cells.
Hangzhou Synrx Therapeutics Technology Co. Ltd. has divulged crystalline salts of DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.
3H Pharmaceuticals Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
CIS Biopharma AG recently presented an antibody-drug conjugate (ADC) targeting the L1 cell adhesion molecule (L1CAM/CD171) as a potential candidate for the treatment of advanced tumors.
Two attractive drug targets in tumors are carbonic anhydrase IX (CAIX), which helps maintain pH homeostasis in the hypoxic tumor, and glutathione peroxidase 4 (GPX4), which can reduce oxidative stress. Researchers from Università degli Studi di Firenze and collaborators aimed to inhibit both CAIX and GPX4 simultaneously.
RSS
